MX2020011781A - Rna formulation for immunotherapy. - Google Patents

Rna formulation for immunotherapy.

Info

Publication number
MX2020011781A
MX2020011781A MX2020011781A MX2020011781A MX2020011781A MX 2020011781 A MX2020011781 A MX 2020011781A MX 2020011781 A MX2020011781 A MX 2020011781A MX 2020011781 A MX2020011781 A MX 2020011781A MX 2020011781 A MX2020011781 A MX 2020011781A
Authority
MX
Mexico
Prior art keywords
immunotherapy
rna
systemic administration
present
rna formulation
Prior art date
Application number
MX2020011781A
Other languages
Spanish (es)
Inventor
Sebastian Kreiter
Mustafa Diken
Heinrich Haas
Daniel Fritz
Martin Meng
Lena Mareen Kranz
Kerstin Reuter
Ugur Sahin
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2020011781A publication Critical patent/MX2020011781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
MX2020011781A 2012-03-26 2014-09-24 Rna formulation for immunotherapy. MX2020011781A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/001319 WO2013143555A1 (en) 2012-03-26 2012-03-26 Rna formulation for immunotherapy

Publications (1)

Publication Number Publication Date
MX2020011781A true MX2020011781A (en) 2020-11-24

Family

ID=48044720

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014011466A MX2014011466A (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy.
MX2020011696A MX2020011696A (en) 2012-03-26 2014-09-24 Rna formulation for immunotherapy.
MX2020011781A MX2020011781A (en) 2012-03-26 2014-09-24 Rna formulation for immunotherapy.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014011466A MX2014011466A (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy.
MX2020011696A MX2020011696A (en) 2012-03-26 2014-09-24 Rna formulation for immunotherapy.

Country Status (19)

Country Link
US (3) US10485884B2 (en)
JP (4) JP6279545B2 (en)
CN (2) CN104302276A (en)
AU (3) AU2013242512B2 (en)
BR (1) BR112014022562A8 (en)
CA (2) CA2864253C (en)
DK (1) DK2830593T3 (en)
ES (2) ES2719480T3 (en)
HK (1) HK1202060A1 (en)
HR (1) HRP20201578T1 (en)
HU (2) HUE052485T2 (en)
LT (2) LT2830593T (en)
MX (3) MX2014011466A (en)
NZ (1) NZ628328A (en)
PT (2) PT2830593T (en)
RS (1) RS61002B1 (en)
SI (1) SI3427723T1 (en)
TR (1) TR201904758T4 (en)
WO (2) WO2013143555A1 (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3590949T (en) 2010-10-01 2022-08-02 Modernatx Inc Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
ES2795110T3 (en) 2011-06-08 2020-11-20 Translate Bio Inc Cleavable lipids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DK3988537T1 (en) 2011-12-07 2022-05-23 Alnylam Pharmaceuticals Inc BIODEGRADABLE LIPIDES FOR DELIVERY OF ACTIVE AGENTS
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
EP3505176A1 (en) 2012-04-02 2019-07-03 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
CA2897858A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
EP3578200A1 (en) 2013-02-22 2019-12-11 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
DK3116900T3 (en) 2014-03-09 2020-09-28 Univ Pennsylvania COMPOSITIONS THAT CAN BE USED TO TREAT ORNITHIN TRANSCARBAMYLASE (OTC) DEFECT
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
ES2931832T3 (en) 2014-06-25 2023-01-03 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for nucleic acid delivery
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
JP6822970B2 (en) 2015-02-26 2021-01-27 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド Cycloolefin polymer container with scratch resistant and antistatic coating
WO2016155809A1 (en) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
JP6912384B2 (en) 2015-04-22 2021-08-04 キュアバック アーゲー RNA-containing compositions for the treatment of cancer diseases
EP3288594B1 (en) 2015-04-27 2022-06-29 The Trustees of The University of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
US11090332B2 (en) * 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017015457A1 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
EP3325018A4 (en) 2015-07-22 2019-04-24 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
EP3341727B1 (en) 2015-08-25 2022-08-10 Duke University Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
EP4286012A2 (en) 2015-09-17 2023-12-06 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US20180318409A1 (en) * 2015-10-22 2018-11-08 Modernatx, Inc. Cancer vaccines
EA201890999A1 (en) * 2015-10-22 2018-12-28 МОДЕРНАТиЭкс, ИНК. VACCINE AGAINST VIRUS HERPES VIRUS
AU2016342048B2 (en) * 2015-10-22 2022-09-08 Modernatx, Inc. Broad spectrum influenza virus vaccine
HUE061564T2 (en) 2015-10-28 2023-07-28 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20190169262A1 (en) * 2015-12-04 2019-06-06 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
JP7080172B2 (en) 2015-12-10 2022-06-03 モデルナティエックス インコーポレイテッド Compositions and Methods for Delivery of Therapeutic Agents
EP4036079A3 (en) 2015-12-22 2022-09-28 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
EP3442590A2 (en) 2016-04-13 2019-02-20 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
EP3458083B1 (en) 2016-05-18 2022-11-02 ModernaTX, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
CA3024500A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
MX2019004913A (en) * 2016-10-26 2019-09-16 Curevac Ag Lipid nanoparticle mrna vaccines.
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US11203569B2 (en) 2017-03-15 2021-12-21 Modernatx, Inc. Crystal forms of amino lipids
PT3596041T (en) 2017-03-15 2023-02-28 Modernatx Inc Compounds and compositions for intracellular delivery of therapeutic agents
EP3609534A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Broad spectrum influenza virus vaccine
CA3057768A1 (en) * 2017-03-31 2018-10-04 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (nmsc)
WO2018191657A1 (en) 2017-04-13 2018-10-18 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
CA3061326A1 (en) 2017-04-27 2018-11-01 The Trustees Of The University Of Pennsylvania Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus
AU2018256877B2 (en) 2017-04-28 2022-06-02 Acuitas Therapeutics, Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
WO2019027055A1 (en) * 2017-08-04 2019-02-07 協和発酵キリン株式会社 Nucleic-acid-containing lipid nanoparticles
EP3668833A1 (en) 2017-08-16 2020-06-24 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
US20200283497A1 (en) 2017-09-13 2020-09-10 Biontech Cell & Gene Therapies Gmbh Rna replicon for expressing at cell receptor or an artificial t cell receptor
AU2018333503A1 (en) 2017-09-13 2020-02-27 BioNTech SE RNA replicon for reprogramming somatic cells
EP3858333A1 (en) * 2017-10-20 2021-08-04 BioNTech RNA Pharmaceuticals GmbH Preparation and storage of liposomal rna formulations suitable for therapy
BR112020016454A8 (en) 2018-02-12 2022-08-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh TREATMENT USING RNA ENCODING CYTOKINE
BR112020026125A8 (en) 2018-03-15 2022-10-18 Biontech Rna Pharmaceuticals Gmbh SUPERIOR OLIGONUCLEOTIDE OR 5'-CAP-TRINUCLEOTIDE COMPOUNDS AND THEIR USES IN RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY
WO2020020444A1 (en) 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
MX2021000801A (en) 2018-07-24 2021-04-12 BioNTech SE Il2 agonists.
US20210170005A1 (en) * 2018-08-15 2021-06-10 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
JP7411258B2 (en) * 2018-09-18 2024-01-11 ユニベルシテイト ゲント Therapeutic nanoparticles and their use
US20220062439A1 (en) 2019-01-10 2022-03-03 Biontech Rna Pharmaceuticals Gmbh Localized administration of rna molecules for therapy
SG11202106987WA (en) 2019-01-11 2021-07-29 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active agents
CN113710702A (en) 2019-01-14 2021-11-26 健泰科生物技术公司 Methods of treating cancer with PD-1 axis binding antagonists and RNA vaccines
WO2020161186A1 (en) 2019-02-08 2020-08-13 Biontech Cell & Gene Therapies Gmbh Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
KR20210124236A (en) 2019-02-08 2021-10-14 비온테크 쎌 & 제네 테라피스 게엠베하 Treatment with CAR-engineered T cells and cytokines
SG11202108691TA (en) 2019-03-12 2021-09-29 BioNTech SE Therapeutic rna for prostate cancer
MX2021011258A (en) 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells.
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
WO2020200481A1 (en) 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Treatment involving interleukin-2 (il2) and interferon (ifn)
JP2022533717A (en) * 2019-05-20 2022-07-25 バイオエヌテック エスエー Therapeutic RNA for ovarian cancer
TW202115105A (en) 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Il2 agonists
WO2021055833A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2021085696A1 (en) * 2019-11-01 2021-05-06 한국과학기술원 Small lipid nanoparticles, and cancer vaccine including same
EP3819377A1 (en) 2019-11-08 2021-05-12 Justus-Liebig-Universität Gießen Circular rna and uses thereof for inhibiting rna-binding proteins
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021129945A1 (en) 2019-12-27 2021-07-01 Biontech Cell & Gene Therapies Gmbh In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)
AU2021212197A1 (en) 2020-01-31 2022-08-04 BioNTech SE Methods of inducing neoepitope-specific T cells with a PD-1 axis binding antagonist and an RNA vaccine
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
AU2021238582A1 (en) * 2020-03-16 2022-09-22 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
WO2021197589A1 (en) 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
EP4132591A4 (en) 2020-04-09 2024-04-24 Verve Therapeutics Inc Base editing of pcsk9 and methods of using same for treatment of disease
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
GB2594365B (en) 2020-04-22 2023-07-05 BioNTech SE Coronavirus vaccine
AU2021286169A1 (en) 2020-06-04 2023-01-19 BioNTech SE RNA replicon for versatile and efficient gene expression
JP2023532768A (en) 2020-07-07 2023-07-31 バイオエヌテック エスエー RNA for treatment of HPV-positive cancer
MX2023000618A (en) 2020-07-17 2023-04-10 Genentech Inc Attention-based neural network to predict peptide binding, presentation, and immunogenicity.
KR20230066395A (en) 2020-09-08 2023-05-15 제넨테크, 인크. Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners
US20230399403A1 (en) 2020-11-11 2023-12-14 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
EP4008785A1 (en) 2020-12-03 2022-06-08 Justus-Liebig-Universität Gießen Circular nucleic acids and uses thereof for interfering with genome expression and proliferation of coronaviruses
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
IT202100003470A1 (en) 2021-02-16 2022-08-16 Fond Toscana Life Sciences VACCINES AGAINST SARS-COV-2
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CA3212571A1 (en) 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
WO2022223617A1 (en) 2021-04-20 2022-10-27 BioNTech SE Virus vaccine
EP4334944A1 (en) 2021-05-04 2024-03-13 BioNTech SE Immunogen selection
AU2022288749A1 (en) 2021-06-08 2023-12-21 Biontech Cell & Gene Therapies Gmbh Agents and methods for activation and targeting of immune effector cells
AU2022317263A1 (en) 2021-07-29 2024-01-04 BioNTech SE Compositions and methods for treatment of melanoma
WO2023030635A1 (en) 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
TW202333803A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023061550A1 (en) 2021-10-11 2023-04-20 BioNTech SE Therapeutic rna for lung cancer
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
CA3234214A1 (en) 2021-10-18 2023-04-27 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
AU2022369342A1 (en) 2021-10-18 2024-03-14 BioNTech SE Modified replicable rna and related compositions and their use
WO2023066923A1 (en) 2021-10-19 2023-04-27 Rahman Nafis Male contraception
WO2023066496A1 (en) 2021-10-21 2023-04-27 BioNTech SE Coronavirus vaccine
EP4238577A3 (en) 2021-10-22 2023-12-06 BioNTech SE Compositions for administration of different doses of rna
WO2023073190A1 (en) 2021-10-28 2023-05-04 BioNTech SE Rna constructs and uses thereof
FR3129833A1 (en) 2021-12-03 2023-06-09 Universite Claude Bernard Lyon 1 NANOPARTICLES FOR THE RELEASE OF NUCLEIC ACIDS
WO2023105005A1 (en) 2021-12-09 2023-06-15 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2023126053A1 (en) 2021-12-28 2023-07-06 BioNTech SE Lipid-based formulations for administration of rna
WO2023147090A1 (en) 2022-01-27 2023-08-03 BioNTech SE Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2023148276A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery to cells
WO2023148277A1 (en) 2022-02-02 2023-08-10 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023213378A1 (en) 2022-05-02 2023-11-09 BioNTech SE Replicon compositions and methods of using same for the treatment of diseases
WO2023217987A1 (en) 2022-05-12 2023-11-16 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023237726A1 (en) 2022-06-10 2023-12-14 Pantarhei Oncology B.V. An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024017479A1 (en) 2022-07-21 2024-01-25 BioNTech SE Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
CN115300641A (en) * 2022-08-01 2022-11-08 深圳市人民医院 Antigen delivery carrier for promoting antigen lysosome escape and activating immune system by targeting dendritic cells and preparation method and application thereof
WO2024028445A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024027910A1 (en) 2022-08-03 2024-02-08 BioNTech SE Rna for preventing or treating tuberculosis
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna
WO2024063788A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064934A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of plasmodium csp antigens and related methods
WO2024063789A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024064931A1 (en) 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of liver stage antigens and related methods
WO2024075022A2 (en) 2022-10-04 2024-04-11 BioNTech SE Rna constructs and uses thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
JPH11510046A (en) 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド Adeno-associated virus liposomes and their use in transfecting dendritic cells to stimulate specific immunity
ES2205209T3 (en) 1996-04-26 2004-05-01 Rijksuniversiteit Te Leiden PROCEDURES FOR SELECTION AND PRODUCTION OF PEPTIDIC EPITHOPES OF T-LYMPHOCYTES AND VACCINES CONTAINING THE INDICATED SELECTED EPITHOPES.
ATE228824T1 (en) 1996-09-13 2002-12-15 Lipoxen Technologies Ltd LIPOSOME COMPOSITION
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
JP2001522603A (en) 1997-11-06 2001-11-20 ロシュ ダイアグノスティックス ゲーエムベーハー Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
CA2345440A1 (en) 1998-10-05 2000-04-13 Charles A. Nicolette Genes differentially expressed in cancer cells to design cancer vaccines
MXPA01011250A (en) 1999-05-06 2002-08-12 Univ Wake Forest Compositions and methods for identifying antigens which elicit an immune response.
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP1242108B1 (en) 1999-12-28 2007-07-11 Pharmexa Inc. Optimized minigenes and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
JP2004530629A (en) 2000-06-07 2004-10-07 バイオシネクサス インコーポレーテッド Immunostimulatory RNA / DNA hybrid molecule
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP1832603B1 (en) 2001-06-05 2010-02-03 CureVac GmbH Stabilised mRNA with increased G/C-content encoding a bacterial antigen and its use
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
ES2329461T3 (en) 2002-06-13 2009-11-26 Merck Patent Gmbh PROCEDURE FOR THE IDENTIFICATION OF ALO-ANTIGENS AND THEIR EMPLOYMENT FOR CANCER THERAPY AND IN THE TRANSPLANT.
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
DE10344799A1 (en) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
WO2005039533A1 (en) 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
ES2357430T3 (en) 2003-10-24 2011-04-26 Immunaid Pty Ltd THERAPY METHOD
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (en) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004057303A1 (en) 2004-11-26 2006-06-01 Merck Patent Gmbh Stable crystal modifications of DOTAP chloride
AU2005321905A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass CD+4 cells in the induction of an immune response
CN105315373B (en) 2005-05-09 2018-11-09 小野药品工业株式会社 The human monoclonal antibodies of programmed death-1 (PD-1) and the method for carrying out treating cancer using anti-PD-1 antibody
KR101607288B1 (en) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. Human monoclonal antibodies to programmed death ligand 1(pd-l1)
HUE043492T2 (en) 2005-08-23 2019-08-28 Univ Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102005041616B4 (en) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2007101227A2 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
DE102006060824B4 (en) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Detection of Individual T Cell Response Patterns Against Tumor-associated Antigens (TAA) in Tumor Patients as a Basis for Individual Therapeutic Vaccination of Patients
NZ629273A (en) 2006-12-27 2015-02-27 Harvard College Compositions and methods for the treatment of infections and tumors
WO2008093195A2 (en) 2007-01-29 2008-08-07 Medipol Sa Chitosan-based colloidal particles for rna delivery
EP1955695A1 (en) * 2007-02-06 2008-08-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nanocapsules of lipophilic complexes of nucleic acids
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
KR101562580B1 (en) 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. Antibodies to human programmed death receptor PD-1
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2009118296A2 (en) 2008-03-24 2009-10-01 4Sc Ag Novel substituted imidazoquinolines
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
PL215513B1 (en) * 2008-06-06 2013-12-31 Univ Warszawski New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
TW201004658A (en) 2008-07-31 2010-02-01 Enzon Pharmaceuticals Inc Nanoparticle compositions for nucleic acids delivery system
JP5382682B2 (en) * 2008-09-01 2014-01-08 国立大学法人 長崎大学 Drug delivery complex
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
DE102008061522A1 (en) 2008-12-10 2010-06-17 Biontech Ag Use of Flt3 ligand to enhance immune responses in RNA immunization
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2769670C (en) 2009-07-31 2018-10-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
KR102017898B1 (en) 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
EP2590626B1 (en) * 2010-07-06 2015-10-28 GlaxoSmithKline Biologicals SA Liposomes with lipids having an advantageous pka-value for rna delivery
PT3590949T (en) 2010-10-01 2022-08-02 Modernatx Inc Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
CN102133404B (en) 2011-03-23 2013-01-16 成都诺恩生物科技有限公司 Tumor targeted therapeutic drug carrier as well as preparation method and application thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
DE102011102734A1 (en) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Device for frothing milk, beverage preparation with this device and method for frothing milk
CN103764121A (en) 2011-07-06 2014-04-30 诺华股份有限公司 Liposomes having useful N:P ratio for delivery of RNA molecules
SG10201605512WA (en) * 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US20150030576A1 (en) 2012-01-10 2015-01-29 Moderna Therapeutics, Inc. Methods and compositions for targeting agents into and across the blood-brain barrier
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2817322B1 (en) 2012-02-20 2016-04-20 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
EP2830593B1 (en) 2012-03-26 2019-02-27 BioNTech RNA Pharmaceuticals GmbH Rna formulation for immunotherapy
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
EP3505176A1 (en) 2012-04-02 2019-07-03 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
JP2015533473A (en) 2012-07-12 2015-11-26 ペルシミューン，インコーポレイテッド Individual cancer vaccine and adaptive immune cell therapy
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
CA2890110C (en) 2012-11-01 2023-05-02 Factor Bioscience Inc. Methods and products for expressing proteins in cells
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
US20160032273A1 (en) 2013-03-15 2016-02-04 Moderna Therapeutics, Inc. Characterization of mrna molecules
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
EP2983804A4 (en) 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ion exchange purification of mrna
WO2014144711A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
JP6702855B2 (en) 2013-04-07 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド Personalized neoplastic vaccine compositions and methods
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015038892A1 (en) 2013-09-13 2015-03-19 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
AU2013401479B2 (en) 2013-09-26 2019-04-04 BioNTech SE Particles comprising a shell with RNA
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
WO2015085318A2 (en) 2013-12-06 2015-06-11 Moderna Therapeutics, Inc. Targeted adaptive vaccines
EP2918275B1 (en) 2013-12-13 2016-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2938700A1 (en) 2014-02-05 2015-08-13 Biontech Ag A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
WO2016091391A1 (en) 2014-12-12 2016-06-16 Curevac Ag Artificial nucleic acid molecules for improved protein expression
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
CN109331176A (en) 2019-02-15
US11559587B2 (en) 2023-01-24
CA2864253C (en) 2020-09-29
NZ628328A (en) 2016-05-27
US20230226217A1 (en) 2023-07-20
US10485884B2 (en) 2019-11-26
HK1202060A1 (en) 2015-09-18
HUE052485T2 (en) 2021-05-28
AU2013242512B2 (en) 2018-01-18
CN109331176B (en) 2022-12-02
CA3088428C (en) 2023-08-01
SI3427723T1 (en) 2020-12-31
LT2830593T (en) 2019-06-25
BR112014022562A8 (en) 2022-10-11
ES2823239T3 (en) 2021-05-06
JP2015514076A (en) 2015-05-18
AU2020202152B2 (en) 2022-12-22
CA2864253A1 (en) 2013-10-03
ES2719480T3 (en) 2019-07-10
WO2013143683A8 (en) 2013-12-12
AU2013242512A1 (en) 2014-08-28
JP6832904B2 (en) 2021-02-24
RS61002B1 (en) 2020-11-30
HRP20201578T1 (en) 2021-03-05
WO2013143683A1 (en) 2013-10-03
MX2020011696A (en) 2020-12-10
US20150086612A1 (en) 2015-03-26
HUE044594T2 (en) 2019-11-28
JP2019031571A (en) 2019-02-28
JP6279545B2 (en) 2018-02-14
CN104302276A (en) 2015-01-21
TR201904758T4 (en) 2019-04-22
PT2830593T (en) 2019-05-06
LT3427723T (en) 2020-12-28
BR112014022562A2 (en) 2017-08-22
CA3088428A1 (en) 2013-10-03
AU2020202152A1 (en) 2020-04-16
JP2020114865A (en) 2020-07-30
JP2018024704A (en) 2018-02-15
AU2017279565A1 (en) 2018-01-18
MX2014011466A (en) 2015-06-03
US20200085974A1 (en) 2020-03-19
JP7096282B2 (en) 2022-07-05
AU2013242512A8 (en) 2014-09-18
PT3427723T (en) 2020-10-12
DK2830593T3 (en) 2019-04-23
WO2013143555A1 (en) 2013-10-03
JP6596478B2 (en) 2019-10-23
AU2017279565B2 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2017279565B2 (en) RNA formulation for immunotherapy
CY1121843T1 (en) MAGNESIUM ION STABILIZED RECEPTOR FORMULATIONS
PH12019501662A1 (en) FORMULATION FOR ANTI-a4á7 ANTIBODY
WO2016142783A3 (en) T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
MX2022006512A (en) Trialkyl cationic lipids and methods of use thereof.
MX2022003698A (en) Nanoparticle compositions and methods for immunotherapy.
MX2019002979A (en) Antibody formulations.
MX363307B (en) Antigen delivery platforms.
EA201290876A1 (en) COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE
WO2013054199A3 (en) Cmv antigens and uses thereof
MX351453B (en) Amphipathic lipid-based sustained release compositions.
WO2011143656A3 (en) Compositions and methods of identifying tumor specific neoantigens
MX363529B (en) Outer membrane vesicles.
EA201790239A1 (en) MOLECULE CARRIER FOR ANTIGENS
CY1123453T1 (en) RNA PREPARATION FOR IMMUNOTHERAPY
EA201500054A1 (en) ATTENUATED VACCINES AGAINST STREPTOCOCCUS SUIS AND METHODS OF THEIR RECEIVING AND APPLICATION
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
MX2015017959A (en) Compositions and methods for immunotherapy.
MX346094B (en) Vaccine delivery method.
MX349657B (en) Protein matrix vaccine compositions including polycations.
MX364946B (en) Improved adjuvant system for oral vaccine adminstration.
MX367773B (en) Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof.
MX2018004308A (en) Foxm1-derived peptide, and vaccine including same.
WO2014184683A3 (en) Compositions and methods for targeting antigen-presenting cells
TN2013000455A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: BIONTECH SE